Tags: ms + treatment.with.MS
-
Neutralizing antibody (NAbs) positivity does not reduce the efficacy of interferon beta-1b (IFNbeta-1b) treatment, according to results of a substudy analysis of patients with a first event suggestive of multiple sclerosis (MS) in a multicentre, randomize
-
In the past few years, it has been shown that many drugs are not equally effective for every patient, and this variability is due, at least in part, to genetic differences.
-
The vaccine incorporates the sequence of myelin basic protein (MBP), which is thought to be one of the targets of MS, and DNA is incorporated into the cells in the body, which then starts to make the protein.
-
The BENEFIT study (BEtaseron in Newly Emerging multiple sclerosis For Initial Treatment), sponsored by Bayer HealthCare, compared Betaseron treatment initiated after a first clinical event with delayed treatment.
-
Kollel Chabad, a social welfare and health promotion organization, has announced the opening of the new Grabski Rehabilitation Center in Migdal Ha'Emek for multiple sclerosis patients who suffer from severe disabilities.
-
Campath-1H is a potentially new treatment for Multiple Sclerosis or MS. It is currently undergoing trials in the UK, USA, Russia, Italy and Croatia to determine whether it can help those with an early form of MS.
First / Previous / Next / Last / Page 1 of 1